Table 8. Impact of expression of enzymes associated with serine/glycine metabolism on disease-free and overall survival tested by log-rank analysis.
| Parameters | Number of patients/recurrence/death | Disease-free survival | Overall survival | ||
| Mean survival (95% CI) months | P-value | Mean survival (95% CI) months | P-value | ||
| PHGDH in tumor | 0.137 | 0.019 | |||
| Negative | 452/36/31 | 128 (125–132) | 132 (129–135) | ||
| Positive | 257/27/28 | 120 (113–127) | 123 (118–128) | ||
| PSAT1 in tumor | 0.507 | 0.225 | |||
| Negative | 526/43/38 | 126 (123–129) | 129 (126–132) | ||
| Positive | 183/20/21 | 124 (118–130) | 127 (122–132) | ||
| PSPH in tumor | 0.042 | 0.005 | |||
| Negative | 611/50/45 | 128 (125–131) | 131 (128–133) | ||
| Positive | 98/13/14 | 107 (99–115) | 117 (108–126) | ||
| PSPH in stroma | 0.097 | 0.004 | |||
| Negative | 625/52/46 | 126 (122–130) | 131 (128–133) | ||
| Positive | 84/11/13 | 117 (107–127) | 116 (106–125) | ||
| SHMT1 in tumor | 0.208 | 0.091 | |||
| Negative | 598/50/46 | 127 (124–130) | 130 (127–133) | ||
| Positive | 111/13/13 | 121 (112–130) | 125 (117–132) | ||
| SHMT1 in stroma | 0.107 | 0.020 | |||
| Negative | 310/34/35 | 121 (115–127) | 126 (121–130) | ||
| Positive | 399/29/24 | 128 (124–132) | 131 (128–134) | ||
| GLDC in tumor | 0.049 | 0.377 | |||
| Negative | 370/42/36 | 122 (116–127) | 129 (125–132) | ||
| Positive | 339/21/23 | 130 (126–134) | 131 (127–135) | ||
| GLDC in stroma | 0.568 | 0.951 | |||
| Negative | 621/54/52 | 126 (122–130) | 130 (127–132) | ||
| Positive | 88/9/7 | 115 (106–124) | 123 (116–130) | ||